<DOC>
	<DOCNO>NCT02081001</DOCNO>
	<brief_summary>The purpose study assess safety , speed absorption , onset action G-Pump™ ( glucagon infusion ) three subcutaneous dos compare Novo GlucaGen® , deliver via OmniPod® infusion pump patient type 1 diabetes .</brief_summary>
	<brief_title>PK/PD Study With G-Pump ( Glucagon Infusion ) T1DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Males female diagnose type 1 diabetes mellitus least 24 month Current usage subcutaneous insulin pump treatment Age 1865 year Cpeptide level &lt; 0.5 ng/ml Willingness follow study procedure , include attend clinic visit Subject provide informed consent sign date informed consent form trialrelated activity Pregnant and/ Lactating : For woman childbearing potential : requirement negative urine pregnancy test agreement use contraception study least 1 month participate study . HbA1c &gt; 10.0 % Renal insufficiency ( serum creatinine 1.2 mg/dL great ) Serum ALT AST equal great 3 time upper limit normal ; hepatic synthetic insufficiency define serum albumin le 3.0 g/dL ; serum bilirubin 2.0 . Hematocrit le equal 34 % Congestive heart failure , NYHA class II , III IV History coronary artery disease Active foot ulceration History cerebrovascular accident Active alcohol abuse substance abuse Active malignancy , except basal cell squamous cell skin cancer Major surgical operation within 30 day prior screen Seizure disorder Current administration oral parenteral corticosteroid Use investigational drug within 30 day prior screen Bleeding disorder , treatment warfarin , platelet count 50,000 Proliferative severe nonproliferative retinopathy Gastroparesis Personal family history pheochromocytoma disorder increase risk pheochromocytoma ( MEN 2 , neurofibromatosis , Von HippelLindau disease ) Insulinoma Allergies glucagon glucagonlike product , history significant hypersensitivity glucagon relate product . Glycogen storage disease Any concurrent illness , diabetes , control stable therapeutic regimen Whole blood donation 1 pint ( 500 mL ) within 8 week prior Screening . Any reason principal investigator deem exclusionary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypoglycemia</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Artificial Pancreas</keyword>
</DOC>